Blood Screening Market Size, Share & Trends Analysis Report By Technology (Nucleic Acid Amplification Test, ELISA, Western Blotting), By Product (Reagent, Instrument), By Region, And Segment Forecasts, 2025 - 2030
This report can be delivered to the clients within 3 Business Days
Blood Screening Market Growth & Trends
The global blood screening market size is expected treach USD 6.62 billion by 2030, registering a CAGR of 11.9% from 2025 t2030, according ta new report by Grand View Research, Inc. The growth of the market is attributed tthe increase in screening of donor and continuous technological advancement by the market players. Demand for blood screening tests is increasing continuously due tincreasing donation, rising awareness about transfusion-transmitted diseases, and technological developments in the industry. Furthermore, governments of various countries are in process tmandates testing all donated blood for several viruses.
Thorough screening is necessary for all donated blood tensure that recipients receive the safest products. As of 2015, such testing consists of screening for red cell antibodies, and the infectious diseases agents: HIV-1, HIV-2, hepatitis virus, West Nile Virus (WNV), Human T-Lymphotropic Virus (HTLV) T. Cruzi, and T. pallidum (syphilis). The result of all these assays must be negative for blood donation.
Technological developments increase the sensitivity and efficiency of the tests. For instance, in 2016, the U.S. FDA approved the Procleix Zika virus assay from Hologic, Inc. and Grifols tscreen donated blood. Furthermore, the U.S. FDA approved next-generation sequencing (NGS) technology in 2013. The technology is cheaper and faster than previous DNA analysis methods.
Blood Screening Market Report Highlights
Blood Screening Market Growth & Trends
The global blood screening market size is expected treach USD 6.62 billion by 2030, registering a CAGR of 11.9% from 2025 t2030, according ta new report by Grand View Research, Inc. The growth of the market is attributed tthe increase in screening of donor and continuous technological advancement by the market players. Demand for blood screening tests is increasing continuously due tincreasing donation, rising awareness about transfusion-transmitted diseases, and technological developments in the industry. Furthermore, governments of various countries are in process tmandates testing all donated blood for several viruses.
Thorough screening is necessary for all donated blood tensure that recipients receive the safest products. As of 2015, such testing consists of screening for red cell antibodies, and the infectious diseases agents: HIV-1, HIV-2, hepatitis virus, West Nile Virus (WNV), Human T-Lymphotropic Virus (HTLV) T. Cruzi, and T. pallidum (syphilis). The result of all these assays must be negative for blood donation.
Technological developments increase the sensitivity and efficiency of the tests. For instance, in 2016, the U.S. FDA approved the Procleix Zika virus assay from Hologic, Inc. and Grifols tscreen donated blood. Furthermore, the U.S. FDA approved next-generation sequencing (NGS) technology in 2013. The technology is cheaper and faster than previous DNA analysis methods.
Blood Screening Market Report Highlights
- Nucleic acid amplification tests (NAT) dominated the market and accounted for the largest revenue share of 41.2% in 2024 attributed tthe increasing prevalence of infectious diseases, such as HIV and hepatitis, necessitating accurate and rapid testing methods that NAATs provide.
- Next Generation Sequencing (NGS) is expected tgrow at a CAGR of 16.5% over the forecast period. The technology has revolutionized genomic analysis by significantly reducing sequencing costs while improving accuracy.
- Reagents led the market and accounted for the largest revenue share of 73.4% in 2024. Reagents are essential components in diagnostic tests, providing the necessary chemical, biological, or immunological substances telicit specific reactions for accurate results.
- Instruments are expected tgrow at the fastest CAGR of 10.8% over the forecast period, owing ttechnological advancements and increasing demand for effective diagnostic solutions.
- North America blood screening market dominated the global market and accounted for the largest revenue share of 38.4% in 2024 attributed tadvanced healthcare infrastructure and a strong emphasis on patient safety.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Technology
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. BLOOD SCREENING MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrant
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
CHAPTER 4. BLOOD SCREENING MARKET: TECHNOLOGY BUSINESS ANALYSIS
4.1. Technology Market Share, 2024 & 2030
4.2. Technology Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Technology, 2018 to 2030 (USD Million)
4.4. Nucleic Acid Amplification Test (NAT)
4.4.1. Nucleic Acid Amplification Test (NAT) Market, 2018 - 2030 (USD Million)
4.5. ELISA
4.5.1. ELISA Market, 2018 - 2030 (USD Million)
4.6. Chemiluminescence Immunoassay (CLIA & EIA )
4.6.1. Chemiluminescence Immunoassay (CLIA & EIA ) Market, 2018 - 2030 (USD Million)
4.7. Next Generation Sequencing (NGS)
4.7.1. Next Generation Sequencing (NGS) Market, 2018 - 2030 (USD Million)
4.8. Western Blotting (WB)
4.8.1. Western Blotting (WB) Market, 2018 - 2030 (USD Million)
CHAPTER 5. BLOOD SCREENING MARKET: PRODUCT BUSINESS ANALYSIS
5.1. Product Market Share, 2024 & 2030
5.2. Product Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
5.4. Reagent
5.4.1. Reagent Market, 2018 - 2030 (USD Million)
5.5. Instrument
5.5.1. Instrument Market, 2018 - 2030 (USD Million)
CHAPTER 6. BLOOD SCREENING MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
6.1. Regional Market Share Analysis, 2024 & 2030
6.2. Regional Market Dashboard
6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.4. North America
6.4.1. North America Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.2. U.S.
6.4.2.1. Key Country Dynamic
6.4.2.2. Regulatory Framework
6.4.2.3. Competitive Insights
6.4.2.4. U.S. Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.3. Canada
6.4.3.1. Key Country Dynamic
6.4.3.2. Regulatory Framework
6.4.3.3. Competitive Insights
6.4.3.4. Canada Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.4. Mexico
6.4.4.1. Key Country Dynamic
6.4.4.2. Regulatory Framework
6.4.4.3. Competitive Insights
6.4.4.4. Mexico Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Europe
6.5.1. Europe Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.2. UK
6.5.2.1. Key Country Dynamic
6.5.2.2. Regulatory Framework
6.5.2.3. Competitive Insights
6.5.2.4. UK Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.3. Germany
6.5.3.1. Key Country Dynamic
6.5.3.2. Regulatory Framework
6.5.3.3. Competitive Insights
6.5.3.4. Germany Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.4. France
6.5.4.1. Key Country Dynamic
6.5.4.2. Regulatory Framework
6.5.4.3. Competitive Insights
6.5.4.4. France Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.5. Italy
6.5.5.1. Key Country Dynamic
6.5.5.2. Regulatory Framework
6.5.5.3. Competitive Insights
6.5.5.4. Italy Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.6. Spain
6.5.6.1. Key Country Dynamic
6.5.6.2. Regulatory Framework
6.5.6.3. Competitive Insights
6.5.6.4. Spain Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.7. Norway
6.5.7.1. Key Country Dynamic
6.5.7.2. Regulatory Framework
6.5.7.3. Competitive Insights
6.5.7.4. Norway Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.8. Denmark
6.5.8.1. Key Country Dynamic
6.5.8.2. Regulatory Framework
6.5.8.3. Competitive Insights
6.5.8.4. Denmark Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.9. Sweden
6.5.9.1. Key Country Dynamic
6.5.9.2. Regulatory Framework
6.5.9.3. Competitive Insights
6.5.9.4. Sweden Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Asia Pacific
6.6.1. Asia Pacific Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.2. Japan
6.6.2.1. Key Country Dynamic
6.6.2.2. Regulatory Framework
6.6.2.3. Competitive Insights
6.6.2.4. Japan Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.3. China
6.6.3.1. Key Country Dynamic
6.6.3.2. Regulatory Framework
6.6.3.3. Competitive Insights
6.6.3.4. China Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.4. India
6.6.4.1. Key Country Dynamic
6.6.4.2. Regulatory Framework
6.6.4.3. Competitive Insights
6.6.4.4. India Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.5. South Korea
6.6.5.1. Key Country Dynamic
6.6.5.2. Regulatory Framework
6.6.5.3. Competitive Insights
6.6.5.4. South Korea Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.6. Australia
6.6.6.1. Key Country Dynamic
6.6.6.2. Regulatory Framework
6.6.6.3. Competitive Insights
6.6.6.4. Australia Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.7. Thailand
6.6.7.1. Key Country Dynamic
6.6.7.2. Regulatory Framework
6.6.7.3. Competitive Insights
6.6.7.4. Thailand Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7. Latin America
6.7.1. Latin America Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7.2. Brazil
6.7.2.1. Key Country Dynamic
6.7.2.2. Regulatory Framework
6.7.2.3. Competitive Insights
6.7.2.4. Brazil Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7.3. Argentina
6.7.3.1. Key Country Dynamic
6.7.3.2. Regulatory Framework
6.7.3.3. Competitive Insights
6.7.3.4. Argentina Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8. MEA
6.8.1. MEA Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8.2. South Africa
6.8.2.1. Key Country Dynamic
6.8.2.2. Regulatory Framework
6.8.2.3. Competitive Insights
6.8.2.4. South Africa Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8.3. Saudi Arabia
6.8.3.1. Key Country Dynamic
6.8.3.2. Regulatory Framework
6.8.3.3. Competitive Insights
6.8.3.4. Saudi Arabia Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8.4. UAE
6.8.4.1. Key Country Dynamic
6.8.4.2. Regulatory Framework
6.8.4.3. Competitive Insights
6.8.4.4. UAE Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8.5. Kuwait
6.8.5.1. Key Country Dynamic
6.8.5.2. Regulatory Framework
6.8.5.3. Competitive Insights
6.8.5.4. Kuwait Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1. Participant Overview
7.2. Company Market Position Analysis
7.3. Company Categorization
7.4. Strategy Mapping
7.5. Company Profiles/Listing
7.5.1. Abbott
7.5.1.1. Overview
7.5.1.2. Financial Performance
7.5.1.3. Product Benchmarking
7.5.1.4. Strategic Initiatives
7.5.2. Danaher Corporation (Beckman Coulter)
7.5.2.1. Overview
7.5.2.2. Financial Performance
7.5.2.3. Product Benchmarking
7.5.2.4. Strategic Initiatives
7.5.3. Becton Dickinson and Company
7.5.3.1. Overview
7.5.3.2. Financial Performance
7.5.3.3. Product Benchmarking
7.5.3.4. Strategic Initiatives
7.5.4. Bio-Rad Laboratories, Inc.
7.5.4.1. Overview
7.5.4.2. Financial Performance
7.5.4.3. Product Benchmarking
7.5.4.4. Strategic Initiatives
7.5.5. Hoffman-La Roche Ltd.
7.5.5.1. Overview
7.5.5.2. Financial Performance
7.5.5.3. Product Benchmarking
7.5.5.4. Strategic Initiatives
7.5.6. Grifols, S.A.
7.5.6.1. Overview
7.5.6.2. Financial Performance
7.5.6.3. Product Benchmarking
7.5.6.4. Strategic Initiatives
7.5.7. Ortho-Clinical Diagnostics, Inc.
7.5.7.1. Overview
7.5.7.2. Financial Performance
7.5.7.3. Product Benchmarking
7.5.7.4. Strategic Initiatives
7.5.8. Siemens Healthcare GmbH
7.5.8.1. Overview
7.5.8.2. Financial Performance
7.5.8.3. Product Benchmarking
7.5.8.4. Strategic Initiatives
7.5.9. Thermo Fisher Scientific, Inc.
7.5.9.1. Overview
7.5.9.2. Financial Performance
7.5.9.3. Product Benchmarking
7.5.9.4. Strategic Initiatives
7.5.10. SOFINA s.a (Biomerieux)
7.5.10.1. Overview
7.5.10.2. Financial Performance
7.5.10.3. Product Benchmarking
7.5.10.4. Strategic Initiatives
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Technology
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. BLOOD SCREENING MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrant
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
CHAPTER 4. BLOOD SCREENING MARKET: TECHNOLOGY BUSINESS ANALYSIS
4.1. Technology Market Share, 2024 & 2030
4.2. Technology Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Technology, 2018 to 2030 (USD Million)
4.4. Nucleic Acid Amplification Test (NAT)
4.4.1. Nucleic Acid Amplification Test (NAT) Market, 2018 - 2030 (USD Million)
4.5. ELISA
4.5.1. ELISA Market, 2018 - 2030 (USD Million)
4.6. Chemiluminescence Immunoassay (CLIA & EIA )
4.6.1. Chemiluminescence Immunoassay (CLIA & EIA ) Market, 2018 - 2030 (USD Million)
4.7. Next Generation Sequencing (NGS)
4.7.1. Next Generation Sequencing (NGS) Market, 2018 - 2030 (USD Million)
4.8. Western Blotting (WB)
4.8.1. Western Blotting (WB) Market, 2018 - 2030 (USD Million)
CHAPTER 5. BLOOD SCREENING MARKET: PRODUCT BUSINESS ANALYSIS
5.1. Product Market Share, 2024 & 2030
5.2. Product Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
5.4. Reagent
5.4.1. Reagent Market, 2018 - 2030 (USD Million)
5.5. Instrument
5.5.1. Instrument Market, 2018 - 2030 (USD Million)
CHAPTER 6. BLOOD SCREENING MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
6.1. Regional Market Share Analysis, 2024 & 2030
6.2. Regional Market Dashboard
6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.4. North America
6.4.1. North America Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.2. U.S.
6.4.2.1. Key Country Dynamic
6.4.2.2. Regulatory Framework
6.4.2.3. Competitive Insights
6.4.2.4. U.S. Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.3. Canada
6.4.3.1. Key Country Dynamic
6.4.3.2. Regulatory Framework
6.4.3.3. Competitive Insights
6.4.3.4. Canada Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.4. Mexico
6.4.4.1. Key Country Dynamic
6.4.4.2. Regulatory Framework
6.4.4.3. Competitive Insights
6.4.4.4. Mexico Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Europe
6.5.1. Europe Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.2. UK
6.5.2.1. Key Country Dynamic
6.5.2.2. Regulatory Framework
6.5.2.3. Competitive Insights
6.5.2.4. UK Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.3. Germany
6.5.3.1. Key Country Dynamic
6.5.3.2. Regulatory Framework
6.5.3.3. Competitive Insights
6.5.3.4. Germany Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.4. France
6.5.4.1. Key Country Dynamic
6.5.4.2. Regulatory Framework
6.5.4.3. Competitive Insights
6.5.4.4. France Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.5. Italy
6.5.5.1. Key Country Dynamic
6.5.5.2. Regulatory Framework
6.5.5.3. Competitive Insights
6.5.5.4. Italy Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.6. Spain
6.5.6.1. Key Country Dynamic
6.5.6.2. Regulatory Framework
6.5.6.3. Competitive Insights
6.5.6.4. Spain Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.7. Norway
6.5.7.1. Key Country Dynamic
6.5.7.2. Regulatory Framework
6.5.7.3. Competitive Insights
6.5.7.4. Norway Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.8. Denmark
6.5.8.1. Key Country Dynamic
6.5.8.2. Regulatory Framework
6.5.8.3. Competitive Insights
6.5.8.4. Denmark Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.9. Sweden
6.5.9.1. Key Country Dynamic
6.5.9.2. Regulatory Framework
6.5.9.3. Competitive Insights
6.5.9.4. Sweden Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Asia Pacific
6.6.1. Asia Pacific Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.2. Japan
6.6.2.1. Key Country Dynamic
6.6.2.2. Regulatory Framework
6.6.2.3. Competitive Insights
6.6.2.4. Japan Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.3. China
6.6.3.1. Key Country Dynamic
6.6.3.2. Regulatory Framework
6.6.3.3. Competitive Insights
6.6.3.4. China Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.4. India
6.6.4.1. Key Country Dynamic
6.6.4.2. Regulatory Framework
6.6.4.3. Competitive Insights
6.6.4.4. India Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.5. South Korea
6.6.5.1. Key Country Dynamic
6.6.5.2. Regulatory Framework
6.6.5.3. Competitive Insights
6.6.5.4. South Korea Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.6. Australia
6.6.6.1. Key Country Dynamic
6.6.6.2. Regulatory Framework
6.6.6.3. Competitive Insights
6.6.6.4. Australia Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.7. Thailand
6.6.7.1. Key Country Dynamic
6.6.7.2. Regulatory Framework
6.6.7.3. Competitive Insights
6.6.7.4. Thailand Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7. Latin America
6.7.1. Latin America Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7.2. Brazil
6.7.2.1. Key Country Dynamic
6.7.2.2. Regulatory Framework
6.7.2.3. Competitive Insights
6.7.2.4. Brazil Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7.3. Argentina
6.7.3.1. Key Country Dynamic
6.7.3.2. Regulatory Framework
6.7.3.3. Competitive Insights
6.7.3.4. Argentina Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8. MEA
6.8.1. MEA Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8.2. South Africa
6.8.2.1. Key Country Dynamic
6.8.2.2. Regulatory Framework
6.8.2.3. Competitive Insights
6.8.2.4. South Africa Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8.3. Saudi Arabia
6.8.3.1. Key Country Dynamic
6.8.3.2. Regulatory Framework
6.8.3.3. Competitive Insights
6.8.3.4. Saudi Arabia Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8.4. UAE
6.8.4.1. Key Country Dynamic
6.8.4.2. Regulatory Framework
6.8.4.3. Competitive Insights
6.8.4.4. UAE Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8.5. Kuwait
6.8.5.1. Key Country Dynamic
6.8.5.2. Regulatory Framework
6.8.5.3. Competitive Insights
6.8.5.4. Kuwait Blood Screening Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1. Participant Overview
7.2. Company Market Position Analysis
7.3. Company Categorization
7.4. Strategy Mapping
7.5. Company Profiles/Listing
7.5.1. Abbott
7.5.1.1. Overview
7.5.1.2. Financial Performance
7.5.1.3. Product Benchmarking
7.5.1.4. Strategic Initiatives
7.5.2. Danaher Corporation (Beckman Coulter)
7.5.2.1. Overview
7.5.2.2. Financial Performance
7.5.2.3. Product Benchmarking
7.5.2.4. Strategic Initiatives
7.5.3. Becton Dickinson and Company
7.5.3.1. Overview
7.5.3.2. Financial Performance
7.5.3.3. Product Benchmarking
7.5.3.4. Strategic Initiatives
7.5.4. Bio-Rad Laboratories, Inc.
7.5.4.1. Overview
7.5.4.2. Financial Performance
7.5.4.3. Product Benchmarking
7.5.4.4. Strategic Initiatives
7.5.5. Hoffman-La Roche Ltd.
7.5.5.1. Overview
7.5.5.2. Financial Performance
7.5.5.3. Product Benchmarking
7.5.5.4. Strategic Initiatives
7.5.6. Grifols, S.A.
7.5.6.1. Overview
7.5.6.2. Financial Performance
7.5.6.3. Product Benchmarking
7.5.6.4. Strategic Initiatives
7.5.7. Ortho-Clinical Diagnostics, Inc.
7.5.7.1. Overview
7.5.7.2. Financial Performance
7.5.7.3. Product Benchmarking
7.5.7.4. Strategic Initiatives
7.5.8. Siemens Healthcare GmbH
7.5.8.1. Overview
7.5.8.2. Financial Performance
7.5.8.3. Product Benchmarking
7.5.8.4. Strategic Initiatives
7.5.9. Thermo Fisher Scientific, Inc.
7.5.9.1. Overview
7.5.9.2. Financial Performance
7.5.9.3. Product Benchmarking
7.5.9.4. Strategic Initiatives
7.5.10. SOFINA s.a (Biomerieux)
7.5.10.1. Overview
7.5.10.2. Financial Performance
7.5.10.3. Product Benchmarking
7.5.10.4. Strategic Initiatives
